Sign in
SuspendedNo phase

A RCT to Assess the Performance of CytoSorb for Shock Reversal in Patients With Vasoplegic Septic Shock

Key facts

Who runs it
CytoSorbents Europe GmbH
Where
Germany18 sites in 1 countryChoose a country to see its sites
Trial code
Status
Suspended
People taking part
260 people, planned
Started
30 Jan 2022
Expected to end
May 2027
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Cytosorb® 300 ml
Record updated
5 August 2025
Why it stopped
Recruitment for the study is currently on hold to allow for a protocol amendment. This revision aims to align the study design with changes in clinical practice since the trial's initiation.

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Patients treated with standard of care (SOC) according to guidelines for sepsis/septic shock for > 6 and < 30 hours prior to randomization
  • Vasoplegic septic shock*, requiring NA ≥ 0.2 µg/kg/min at the time of randomization, despite adequate fluid resuscitation to maintain MAP ≥ 65 mmHg after at least 6 hours of guideline-oriented initial therapy, including continuous NA administration
  • Lactate >2 mmol/l and <8 mmol/l at baseline
  • IL-6 ≥ 1000 ng/l at screening
  • Minimum 18 years of age
  • Provide voluntary consent to participate in the study either directly or via a legally authorized representative (LAR) or in accordance to the procedure after determination of an emergency situation according to Art. 68 (1) MDR, as applicable; (Septic shock is defined according to the SCCM / EISCM task force Sepsis-3 definition [Singer 2016])

Who cannot take part

  • Patients with a steroid therapy above Cushing-threshold dose (e.g. 30 mg hydrocortisone/d or 6 mg prednisolone/d) for more than 30 days prior to baseline
  • Cytokine-specific antibody therapy before inclusion
  • Anticipated interruption of CytoSorb® therapy for more than 2 hours within the first 26 hours after start of intervention
  • Cancer patients currently on chemotherapy with cytostatics, tyrosine kinase inhibitors, or a treatment with antibodies (e.g. PD-1-inhibitors)
  • Patients with an abdominal source of infection without a source control intervention at the time of randomization OR a planned additional surgical intervention within the first 28 hours after randomization
  • Conditions with a poor 90-day chance of survival because of an uncorrectable medical condition such as poorly controlled neoplasm, or other moribund end-stage disease states in which death was perceived to be imminent
  • Administration of any other vasopressors than NA at time of randomization and within the first 28 hours after randomization
  • Indication for va-ECMO at baseline OR a planned va-ECMO within the first 28 hours after randomization
  • Acute traumatic brain injury
  • Decision to limit or withdraw treatment within the study and/or observation period in the ICU
  • Pregnancy / breast feeding
  • Participation in another interventional study

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To assess the performance of the CytoSorb® 300 mL device for shock reversal in patients with vasoplegic septic shock.

The 2 groups in the trial

  • SoC+CytoSorb treatmentTreatment being tested

    patients allocated to this group, will receive CytoSorb therapy in addition to the standard of care therapy according to applicable guidelines

    Treatment: Cytosorb® 300 ml

  • Standard of Care (SoC)No study treatment, for comparison

    patients allocated to this group will receive only standard of care therapy according to applicable guidelines

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Randomized, Multicenter, Single-blind, Controlled Study to Assess the Performance of the Cytosorb® 300 ml Device for Shock Reversal in Patients With Vasoplegic Septic Shock
Record updated
5 August 2025